![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP
RNS Number : 1089P
GW Pharmaceuticals PLC
15 February 2016
GW Pharmaceuticals PLC Director/PDMR Shareholding
GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company", "GW")
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
Cambridge, UK, 15 February 2016: GW Pharmaceuticals (NASDAQ: GWPH, AIM: GWP) hereby provides notification that the Company has today granted the following awards to Directors over the Company's Ordinary shares ("Shares") in the form of options ("Awards") under the GW Pharmaceuticals plc Long-Term Incentive Plan, which was approved by shareholders on 18 March 2008:
Name Number of Ordinary Equivalent number Shares under of ADS's under this Option this Option Award Award ------------------- --------------------- -------------------- Justin Gover 739,037 61,586 ------------------- --------------------- -------------------- Julian Gangolli 668,024 55,669 ------------------- --------------------- -------------------- Dr Geoffrey Guy 631,344 52,612 ------------------- --------------------- -------------------- Dr Stephen Wright 288,285 24,024 ------------------- --------------------- -------------------- Chris Tovey 254,754 21,229 ------------------- --------------------- -------------------- Adam George 234,649 19,554 ------------------- --------------------- --------------------
25% of the Awards are in the form of market-priced options, whereby the options have an exercise price equivalent to the market price at market close on the day prior to grant ($44.64 per ADS, equivalent to 257 pence per Ordinary Share). These options become exercisable on the third anniversary of the date of grant. Future gains upon exercise of these options will be linked to the extent of share price growth over the vesting period. The Remuneration Committee consider that this element of the Awards will help to ensure continuing alignment between executive and shareholders' interests.
50% of the Awards are in the form of Performance stock options, whereby the options will vest upon the third anniversary of the date of grant subject to certain corporate performance conditions having been achieved. In this case, vesting of half of the Performance stock options will occur upon receipt from FDA of their confirmation of acceptance of an Epidiolex NDA filing and half will vest upon FDA grant of Epidiolex regulatory approval. The Remuneration Committee considers these particular milestones to be the most important elements of our agreed strategy and the key value drivers for the business at this time.
25% of the Awards are in the form of Restricted stock options whereby these options are subject to a four year service condition and vesting period. 25% of the options will vest on each anniversary of the date of grant over the next four years. The Remuneration Committee consider that this element of the Awards should help to ensure retention of our team of executive Directors, a key factor for GW's future success.
In general, the Awards may be exercised at any time between the vesting date and the tenth anniversary of the date of grant. Our US based Directors will be required to exercise their Performance stock and Restricted stock options within six months of the vesting date. The exercise price of the Performance stock option and Restricted stock options is 0.1p per Ordinary Share, being the par value of the Shares. Awards which do not vest at the end of the vesting period will lapse permanently.
Following this Award, the total number of Options held by each of the executive Directors is as follows:
Name Total number Equivalent number of Ordinary of ADS's over Shares over which option which option awards are now awards are now held: held: ------------------- ----------------- -------------------- Justin Gover 1,430,117 119,176 ------------------- ----------------- -------------------- Julian Gangolli 927,269 77,272 ------------------- ----------------- -------------------- Dr Geoffrey Guy 1,392,423 116,035 ------------------- ----------------- -------------------- Dr Stephen Wright 1,305,733 108,811 ------------------- ----------------- -------------------- Chris Tovey 743,377 61,948 ------------------- ----------------- -------------------- Adam George 813,818 67,818 ------------------- ----------------- --------------------
For further information, please contact:
GW Pharmaceuticals PLC +44 (0)1980 557 000
Adam George, Company Secretary
Peel Hunt LLP (Nominated Adviser)
James Steel/Oliver Jackson +44 (0) 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSLLFVSFTIELIR
(END) Dow Jones Newswires
February 15, 2016 09:39 ET (14:39 GMT)
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions